|
Feb 25, 2021
|
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
|
|
|
Feb 25, 2021
|
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
|
|
|
Feb 18, 2021
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Feb 11, 2021
|
BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
|
|
|
Feb 09, 2021
|
BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
|
|
|
Feb 03, 2021
|
BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
|
|
|
Feb 02, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jan 22, 2021
|
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
|
|
|
Jan 07, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jan 06, 2021
|
BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
|
|
